Suvretta Capital Management, LLC Chinook Therapeutics, Inc. Transaction History

Suvretta Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$18.66 - $38.58 $3.35 Million - $6.92 Million	179,344 Added 11.43%	1,748,141 $67.2 Million
Q1 2023 May 15, 2023	BUY	$21.53 - $26.8 $2.67 Million - $3.32 Million	123,967 Added 8.58%	1,568,797 $36.3 Million
Q4 2022 Feb 14, 2023	BUY	$18.63 - $27.35 $1.02 Million - $1.5 Million	54,830 Added 3.94%	1,444,830 $37.9 Million
Q3 2022 Nov 14, 2022	SELL	$17.51 - $23.37 $6.9 Million - $9.21 Million	-394,200 Reduced 22.09%	1,390,000 $27.3 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $4.41 Million - $6.58 Million	350,000 Added 24.4%	1,784,200 $31.2 Million
Q1 2022 May 16, 2022	BUY	$12.02 - $16.69 $2.24 Million - $3.12 Million	186,732 Added 14.97%	1,434,200 $23.5 Million
Q4 2021 Feb 14, 2022	BUY	$10.69 - $16.83 $2.14 Million - $3.37 Million	200,000 Added 19.09%	1,247,468 $20.3 Million
Q3 2021 Nov 15, 2021	BUY	$11.5 - $14.86 $913,617 - $1.18 Million	79,445 Added 8.21%	1,047,468 $13.4 Million
Q2 2021 Aug 16, 2021	BUY	$13.6 - $18.98 $5.69 Million - $7.94 Million	418,408 Added 76.13%	968,023 $13.7 Million
Q1 2021 May 17, 2021	BUY	$14.17 - $19.11 $328,177 - $442,587	23,160 Added 4.4%	549,615 $8.54 Million
Q4 2020 Feb 16, 2021	BUY	$11.9 - $20.91 $6.26 Million - $11 Million	526,455 New	526,455 $8.35 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Suvretta Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Suvretta Capital Management, LLC with notifications on news.